臨床腫瘍学: 症例報告

Organoselenium Compounds as Novel Adjuvants of Chemotherapy Drugs

Elena Johnson*

Organoselenium compounds have emerged as promising candidates for augmenting the efficacy of chemotherapy drugs in the treatment of cancer. Characterized by the incorporation of selenium into organic molecules, these compounds possess diverse biological activities that make them attractive candidates for combination therapy strategies. Preclinical studies have demonstrated that organoselenium compounds exhibit intrinsic anticancer properties and can synergistically enhance the cytotoxic effects of conventional chemotherapy drugs by modulating cellular pathways involved in drug resistance and tumor progression. Moreover, these compounds have shown the potential to mitigate chemotherapy-induced side effects, such as oxidative stress and inflammation, thereby improving patient tolerance to treatment. However, the clinical translation of organoselenium-based adjunct therapies necessitates further investigation to elucidate their pharmacokinetic properties, optimal dosing regimens, and potential drug interactions. Large-scale clinical trials are warranted to validate the therapeutic benefits of organoselenium compounds and establish their role in improving patient outcomes in the clinical setting.